Dmitri Bobilev

1.1k total citations · 1 hit paper
20 papers, 305 citations indexed

About

Dmitri Bobilev is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Dmitri Bobilev has authored 20 papers receiving a total of 305 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Dmitri Bobilev's work include Cancer Immunotherapy and Biomarkers (4 papers), Clostridium difficile and Clostridium perfringens research (4 papers) and Ovarian cancer diagnosis and treatment (3 papers). Dmitri Bobilev is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Clostridium difficile and Clostridium perfringens research (4 papers) and Ovarian cancer diagnosis and treatment (3 papers). Dmitri Bobilev collaborates with scholars based in United States, Israel and United Kingdom. Dmitri Bobilev's co-authors include Jason M. Norman, Bernat Olle, David Geffen, Rajita Menon, Candida Fratazzi, Mary Ruisi, Thomas Louie, Jeffrey L. Silber, Sahil Khanna and Nathalie Erpelding and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Dmitri Bobilev

19 papers receiving 302 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection

2023 120 citations Thomas Louie, Yoav Golan et al. JAMA profile →

Peers

Countries citing papers authored by Dmitri Bobilev

Since Specialization

Citations

This map shows the geographic impact of Dmitri Bobilev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dmitri Bobilev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dmitri Bobilev more than expected).

Fields of papers citing papers by Dmitri Bobilev

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dmitri Bobilev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dmitri Bobilev. The network helps show where Dmitri Bobilev may publish in the future.

Co-authorship network of co-authors of Dmitri Bobilev

This figure shows the co-authorship network connecting the top 25 collaborators of Dmitri Bobilev. A scholar is included among the top collaborators of Dmitri Bobilev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dmitri Bobilev. Dmitri Bobilev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	607 CONSORTIUM-IO: a phase 1 study evaluating a combination of an 11-strain bacterial consortium (VE800) and nivolumab in treatment of select refractory or metastatic cancers 2024 ·Regular and Young Investigator Award Abstracts ·(unknown), Amanda Prince, (unknown), (unknown), Rajita Menon, Jason M. Norman, Rose L. Szabady, Dmitri Bobilev, (unknown), Jeremiah J. Faith, Jeffrey L. Silber, Bernat Olle, Diwakar Davar	2
2	VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection breakdown → 2023 ·JAMA ·Thomas Louie, Yoav Golan, Sahil Khanna, Dmitri Bobilev, Nathalie Erpelding, Candida Fratazzi, (unknown), Rajita Menon, Mary Ruisi, Jason M. Norman, Jeremiah J. Faith, Bernat Olle, (unknown), Jeffrey L. Silber, Darrell S. Pardi	120
3	109: AN 8-STRAIN, RATIONALLY DEFINED BACTERIAL CONSORTIUM, VE303, REDUCES THE RISK OF CLOSTRIDIOIDES DIFFICILE INFECTION (CDI) RECURRENCE COMPARED WITH PLACEBO IN ADULTS AT HIGH RISK FOR RECURRENCE: RESULTS OF THE PHASE 2 CONSORTIUM STUDY 2022 ·Gastroenterology ·Thomas Louie, Yoav Golan, Sahil Khanna, (unknown), Candida Fratazzi, (unknown), Mary Ruisi, Nathalie Erpelding, (unknown), Dmitri Bobilev, Jeffrey L. Silber, Darrell S. Pardi	2
4	Abstract LB107: Novel transcriptional signatures associated with antitumor activity in vidutolimod (vidu)-treated patients (pts) with anti-PD-1-refractory melanoma and non-small cell lung cancer (NSCLC) 2022 ·Cancer Research ·Hong Liu, Luping Zhao, Ping Zheng, Riyue Bao, Jason J. Luke, Marcelo V. Negrão, (unknown), George J. Weiner, (unknown), Dmitri Bobilev, James E. Wooldridge, Arthur Μ. Krieg	0
5	CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma. 2021 ·Journal of Clinical Oncology ·Deborah J. Wong, Aru Panwar, Ari J. Rosenberg, Vidhya Karivedu, Douglas Laux, Dan P. Zandberg, Dmitri Bobilev, Luping Zhao, James E. Wooldridge, (unknown), Ezra E.W. Cohen	3
6	Abstract CT246: Consortium-IO: A safety and efficacy study of VE800 in combination with nivolumab in previously treated patients with select advanced metastatic cancers 2020 ·Cancer Research ·Diwakar Davar, Judy S. Wang, Michael Cecchini, Zev A. Wainberg, Martin Gutierrez, Anita Turk, Rose L. Szabady, Jason M. Norman, Bernat Olle, Bruce Roberts, Dmitri Bobilev	4
7	1953. VE303, a Rationally Designed Bacterial Consortium for Prevention of Recurrent Clostridioides difficile (C. Difficile) infection (rCDI), Stably Restores the Gut Microbiota After Vancomycin (vanco)-Induced Dysbiosis in Adult Healthy Volunteers (HV) 2019 ·Open Forum Infectious Diseases ·Dmitri Bobilev, Shakti K. Bhattarai, Rajita Menon, Brian Klein, (unknown), Bernat Olle, Bruce Roberts, Vanni Bucci, Jason M. Norman	12
8	A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas 2019 ·British Journal of Cancer ·Chia‐Chi Lin, Hendrik-Tobias Arkenau, Sharon Lu, Jasgit C. Sachdev, Javier de Castro, Monica Mita, Rafał Dziadziuszko, Wu‐Chou Su, Dmitri Bobilev, (unknown), (unknown), (unknown), Glen J. Weiss	18
9	Mo1955 – Ve303, a Live Biotherapeutic Product for Prevention of Recurrent Clostridioides Difficile (C. Difficile) Infection. Preliminary Results of a Phase 1, Open-Label Healthy Volunteers Study of Oral Ve303 After Vancomycin 2019 ·Gastroenterology ·Dmitri Bobilev, (unknown), Paolo B. DePetrillo, Brian Klein, (unknown), Bernat Olle, Bruce Roberts, Jason M. Norman	3
10	Dose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cancer (OC) (TOPACIO/Keynote-162) 2017 ·Annals of Oncology ·Panagiotis A. Konstantinopoulos, Jasgit C. Sachdev, Lee S. Schwartzberg, Ursula A. Matulonis, Peiqing Sun, (unknown), Wei Guo, Dmitri Bobilev, Gursel Aktan, Vassiliki Karantza, Bruce J. Dezube, (unknown)	9
11	Safety, pharmacodynamic, and pharmacokinetic profile of TSR-042, an anti–PD–1 monoclonal antibody, in patients (pts) with advanced solid tumors 2017 ·Annals of Oncology ·Jasgit C. Sachdev, Amita Patnaik, (unknown), Jody Pelusi, Muralidhar Beeram, E. Im, David W. Jenkins, Kristen McEachern, Sharon Lu, Wei Guo, (unknown), (unknown), Dmitri Bobilev, Vikram Kansra, Glen J. Weiss	7
12	Phase I/II study of niraparib plus pembrolizumab in patients with triple-negative breast cancer or recurrent ovarian cancer (KEYNOTE-162). 2016 ·Journal of Clinical Oncology ·Panagiotis A. Konstantinopoulos, Kathleen N. Moore, Jasgit C. Sachdev, Monica Mita, Shaveta Vinayak, Shelly Seward, Vassiliki Karantza, Gursel Aktan, Andrew R. Ferguson, Dmitri Bobilev, Ursula A. Matulonis	7
13	Adjuvant brachytherapy for Stage IB Grade 2 endometrial carcinoma: Multivariate analysis of a single institution experience 2016 ·Indian Journal of Medical and Paediatric Oncology ·(unknown), (unknown), Dmitri Bobilev, Wilmosh Mermershtain	1
14	Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer. 2015 ·Journal of Clinical Oncology ·Hendrik‐Tobias Arkenau, Jasgit C. Sachdev, Monica Mita, Rafał Dziadziuszko, Chia‐Chi Lin, James Chih‐Hsin Yang, Jeffrey R. Infante, Stephen P. Anthony, Mark Voskoboynik, Wu‐Chou Su, Javier de Castro, Ronald B. Natale, Zhiyi Zhang, (unknown), Dmitri Bobilev, Glen J. Weiss	27
15	Topoisomerase I as a target of erlotinib and gefitinib: Efficacy of combined treatments with camptothecin 2014 ·International Journal of Oncology ·(unknown), Dmitri Bobilev, Esther Priel	13
16	Efficacy of cabazitaxel in mouse models of pediatric brain tumors 2014 ·Neuro-Oncology ·Emily J. Girard, Sally Ditzler, Donghoon Lee, Andrew Richards, Kevin Yagle, Joshua Park, Hedieh K. Eslamy, Dmitri Bobilev, Patricia Vrignaud, James M. Olson	27
17	A phase I/II study of cabazitaxel (Cbz) combined with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after docetaxel (D) chemotherapy: Preliminary results. 2013 ·Journal of Clinical Oncology ·Christophe Massard, Carmel Pezaro, Dmitri Bobilev, Aurelius Omlin, Diletta Bianchini, (unknown), Laurence Albigès, Yohann Loriot, Andréa Varga, (unknown), Karim Fizazi, Johann S. de Bono	4
18	Combined Multimodal Approach to the Treatment of Metastatic Anal Carcinoma: Report of a Case and Review of the Literature 2006 ·Oncology Research and Treatment ·(unknown), Dmitri Bobilev, (unknown), David Geffen, Shlomo Walfisch	22
19	Disseminated intravascular coagulation at presentation of advanced gastric cancer. 2006 ·PubMed ·(unknown), Dmitri Bobilev, Samuel Ariad, David Geffen	22
20	Diabetes insipidus caused by isolated intracranial metatstases in patient with breast cancer 2005 ·Journal of Neuro-Oncology ·Dmitri Bobilev, Ilan Shelef, Konstantin Lavrenkov, (unknown), Sofia Man, (unknown), Samuel Ariad	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact